Hematology

Potential Control of GVHD via HSVtk/GCV Gene Therapy

Published in Gene Therapy Weekly, March 17th, 1997

Thymidine kinase (TK) gene-transduced human lymphocytes potentially could hold the key which allows the graft-vs-leukemia (GVL) effect to function in allogeneic transplantations while maintaining control over graft-vs-host disease (GVHD).

Selective patients with hematologic malignancies (e.g., multiple myeloma) have been cured by allogeneic bone marrow transplantations. A large portion of this procedure's curative potential depends on an antitumor effect derived from the adoptive transfer of immunocompetent cells present in the donor graft, also known as GVL.

Unfortunately, the same cells that stimulate this GVL effect are also responsible for GVHD....

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1997-03-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry